Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Haematol

Title: The Lancet. Haematology

Publisher: Elsevier BV

ISSN (Electronic): 2352-3026

ISSN (Print): 2352-3026

Publication date (Electronic): Dec 2020

Volume: 7

Issue: 12

Affiliations

[1 ] Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

[2 ] Hematology, University Hospital Hôtel-Dieu, Nantes, France.

[3 ] Centre Hospitalier, Le Mans, France.

[4 ] Centre Hospitalier Universitaire de Limoges, Limoges, France.

[5 ] Centre Hospitalier Régional Universitaire-Hôpital du Bocage, Angers, France.

[6 ] Centre Hospitalier H Duffaut, Avignon, France.

[7 ] Hôpital de Mercy (Centre Hospitalier Régional Metz-Thionville), Metz, France.

[8 ] Hôpital St-Louis, Paris, France.

[9 ] Hôpital Necker, Paris, France.

[10 ] Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands.

[11 ] Meander Medical Centre, Amersfoort, Netherlands.

[12 ] Erasmus MC Cancer Institute, Rotterdam, Netherlands.

[13 ] Zuyderland MC, Sittard, Netherlands.

[14 ] Janssen Global Services, Raritan, NJ, USA.

[15 ] Janssen Research and Development, Beerse, Belgium.

[16 ] Janssen Research and Development, Leiden, Netherlands.

[17 ] Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: p.sonneveld@erasmusmc.nl.

Article

Publisher Item ID: S2352-3026(20)30356-2

DOI: 10.1016/S2352-3026(20)30356-2

PubMed ID: 33242444

SO-VID: 02d9b14e-c67f-46ad-8932-cf0e9e5e12b8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 10

See all cited by